Jingze Biopharmaceutical Files for Hong Kong IPO with Post-Money Valuation of RMB 3.21 Billion

Jul 06, 2026 16:06 CST Updated 16:06

Jingze Bio

New Drug Developer

On July 3, the HKEX website showed that Jingze Bio submitted an application for an IPO on the Hong Kong Stock Exchange.

Jingze Bio, established in 2014, focuses on the two major sectors of assisted reproduction and ophthalmology.Founder andGeneral ManagerForMr. Peng Hongwei, owner of the company32.13%Equity.

Since 2018,Jingze Bio hasCompleted 6 rounds of financing, with cumulative fundraising of approximately1.041 billion yuan. The post-money valuation from the previous funding round was RMB 3.21 billion.

Financing Round	Financing Amount	Post-money Valuation
Pre-Series A	RMB 30 million	RMB 200 million
Series A	RMB 19 million	420 million yuan
Series B	RMB 45 million	770 million yuan
Series B+	RMB 96.1 million	RMB 870 million
Series C	240 million yuan	RMB 1.94 billion
Series C+	RMB 606 million	RMB 3.21 billion

Currently,Jingze Bio’s pipeline includes biosimilars, improved new drugs, and innovative drugs, among which JZB30 (recombinant human follicle-stimulating hormoneBiosimilars) and JZB05 (aflibercept biosimilar) as the core projects.

JZB30 was approved for marketing in China in 2025,The brand name is Zepanxi,Indicated for ① women with anovulation (including polycystic ovary syndrome) who are unresponsive to clomiphene citrate treatment;②Undergoing controlled ovarian hyperstimulation or assisted reproductive technologies (such asIn Vitro Fertilization-Embryo Transfer, Gamete Intrafallopian Transfer, and Zygote Intrafallopian Transfer）of the population, to promote multifollicular development;③ Patients with severe deficiency of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), i.e., those with endogenous serum LH levels <1.2 IU/L. Combined administration of LH and FSH is recommended to stimulate follicular development.

This product'sExclusive commercialization rights granted in 2025CMS Pharmaceutical, expected to be officially commercialized in 2027.

JZB05 is currently undergoing Phase III clinical trials, with its exclusive commercialization rights granted in 2025.CMS Pharmaceutical Group.Jingze Bio expects the drug to complete Phase III studies and submit a marketing application in the second half of this year.

The prospectus shows that, as of April 30, 2026,Jingze Bio reported a net loss of approximately RMB 89.32 million, with total liabilities reaching RMB 1.927 billion and cash reserves of only RMB 81.05 million.

Copyright © 2026 PHARMCUBE. All Rights Reserved. Disclaimer: The information contained in this WeChat article is for general reference only and shall not be used directly as a basis for decision-making. PharmaCube assumes no liability for any losses incurred by any party arising from the use of the content herein.